Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)

Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 1, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	3,910,196	4,162,126	3,888,242	2,358,729	2,194,737	1,434,322
Market Cap Growth	10.18%	7.04%	64.84%	7.47%	53.02%	69.69%
Enterprise Value	3,675,270	3,989,271	3,792,904	2,296,495	2,136,376	1,424,670
Last Close Price	1629.70	1729.01	1600.48	962.02	885.56	572.68
PE Ratio	37.68	38.08	40.60	27.84	67.06	49.39
Forward PE	33.17	35.80	42.36	28.97	28.54	26.49
PS Ratio	7.27	7.92	8.02	5.38	5.68	4.28
PB Ratio	5.39	5.74	5.79	3.98	4.30	2.90
P/TBV Ratio	7.21	7.67	8.39	6.16	6.23	4.16
P/FCF Ratio	-	34.85	39.14	82.08	29.30	28.69
P/OCF Ratio	-	29.58	32.04	47.56	24.43	23.25
PEG Ratio	2.98	2.39	2.97	1.99	1.46	1.31
EV/Sales Ratio	6.83	7.59	7.82	5.23	5.53	4.25
EV/EBITDA Ratio	23.76	26.65	29.46	19.71	21.04	17.07
EV/EBIT Ratio	28.36	31.65	36.05	24.68	26.19	22.17
EV/FCF Ratio	-	33.40	38.18	79.91	28.53	28.49
Debt / Equity Ratio	0.03	0.03	0.05	0.12	0.03	0.08
Debt / EBITDA Ratio	0.15	0.16	0.25	0.58	0.13	0.46
Debt / FCF Ratio	-	0.20	0.33	2.40	0.17	0.77
Asset Turnover	-	0.59	0.58	0.58	0.56	0.49
Inventory Turnover	-	1.10	1.08	1.12	1.17	1.05
Quick Ratio	-	2.17	1.82	1.36	1.37	1.20
Current Ratio	-	2.89	2.56	2.00	2.03	1.89
Return on Equity (ROE)	-	15.71%	15.20%	15.43%	6.74%	4.61%
Return on Assets (ROA)	-	8.87%	7.91%	7.73%	7.42%	5.91%
Return on Capital (ROIC)	11.17%	10.85%	9.63%	9.81%	9.64%	7.25%
Return on Capital Employed (ROCE)	-	17.10%	15.40%	15.30%	15.50%	12.50%
Earnings Yield	2.65%	2.63%	2.46%	3.59%	1.49%	2.02%
FCF Yield	-	2.87%	2.56%	1.22%	3.41%	3.49%
Dividend Yield	0.94%	0.92%	0.84%	1.20%	1.13%	1.31%
Payout Ratio	-	33.07%	30.26%	29.73%	65.97%	53.70%
Buyback Yield / Dilution	-0.00%	-	-	-	-	-
Total Shareholder Return	0.94%	0.92%	0.84%	1.20%	1.13%	1.31%

Updated Jan 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.